Endometrial Cancer Indications Expanded for Pembrolizumab
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug...
Progress Against Cancer
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients...
The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration...
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. ...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration...
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and...
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET...
Tarlatamab-dlle is the first bispecific T-cell engager approved to treat a solid tumor. The U.S. Food and Drug Administration (FDA)...
The CAR T-cell therapy received accelerated approval to treat advanced cases of pretreated follicular lymphoma. The U.S. Food and...